-
公开(公告)号：WO2013066151A1
公开(公告)日：2013-05-10
申请号：PCT/NL2011/050737
申请日：2011-10-31
IPC分类号： A61K31/202 , A61K31/7072 , A61K45/06 , A61P25/00
CPC分类号： A61K31/7072 , A23L5/00 , A23L33/12 , A23L33/13 , A23V2002/00 , A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K31/714 , A61K33/04 , A61K45/06 , A61K2300/00 , A23V2200/322 , A23V2250/1626 , A23V2250/1868 , A23V2250/187 , A23V2250/7052 , A23V2250/7056 , A23V2250/706 , A23V2250/708 , A23V2250/712
摘要： The invention relates to a composition for use in the treatment or prevention of recognition dysfunction, and/or for improving recognition, in a (prodromal) Alzheimer's patient, in particular in a drug-naive (prodromal) Alzheimer's patient, more particularly in a subject with a mini-mental state examination of 20–30.
摘要翻译： 本发明涉及用于治疗或预防（前驱）阿尔茨海默病患者中的识别功能障碍和/或用于改善识别的组合物，特别是用于初始药物（前驱） 阿尔茨海默病患者，更特别是在患有20-30微型精神状态检查的受试者中。
-
2.发明申请USE OF RESVERATROL OR ANOTHER HYDROXYLATED STILBENE FOR PRESERVING COGNITIVE FUNCTIONING 审中-公开还原剂或其他羟基苯磺酸钠用于保存认知功能的用途
公开(公告)号：WO2010095943A2
公开(公告)日：2010-08-26
申请号：PCT/NL2010/050085
申请日：2010-02-19
申请人： N.V. NUTRICIA , VAN DER BEEK, Eline Marleen , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
发明人： VAN DER BEEK, Eline Marleen , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
CPC分类号： A61K31/05 , A23L2/52 , A23L33/105 , A23L33/127 , A23V2002/00 , A23V2250/54246 , A23V2250/54252 , A23V2250/5114 , A23V2250/2132 , A23V2200/322
摘要： The present invention relates to the use of an hydroxylated stilbene, in particular resveratrol, in the manufacture of a neutraceutical composition for increasing the mi- crovascular plasticity and/or microvessel density, and/or decreasing the microvessel abnormalities in the brain, in particular in the hippocampus of a mammal, in particular for the treatment of age- and condition-related decline in brain neuronal function and/or cognitive functioning in a mammal. In particular, the condition is selected from the group of Alzheimer's Disease, dementia, depression, sleep disorders, impaired memory function, psychoses, Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, ADHD and anxiety.
摘要翻译： 本发明涉及羟基化二苯乙烯，特别是白藜芦醇在制备用于增加微血管可塑性和/或微血管密度和/或降低脑中微血管异常的中性药物组合物中的用途，特别是在 哺乳动物的海马，特别是用于治疗哺乳动物的脑神经元功能和/或认知功能的年龄和状况相关的下降。 特别地，该病症选自阿尔茨海默氏病，痴呆，抑郁症，睡眠障碍，记忆障碍受损，精神病，帕金森病，亨廷顿舞蹈病，癫痫，精神分裂症，偏执狂，ADHD和焦虑症。
-
3.发明申请METHOD FOR TREATING, STABILIZING OR SLOWING DOWN BRAIN GLUCOSE METABOLISM DEFICIT 审中-公开治疗，稳定或缓慢下降脑葡萄糖代谢缺陷的方法
公开(公告)号：WO2015115886A1
公开(公告)日：2015-08-06
申请号：PCT/NL2014/050059
申请日：2014-01-31
申请人： N.V. NUTRICIA
发明人： BROERSEN, Ladislaus Maria , HAGEMAN, Robert Johan Joseph , LANSBERGEN, Marieke , GROENENDIJK, Martine , DE WILDE, Mattheus Cornelis
IPC分类号： A23L1/30 , A61K45/06 , A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61P25/28
CPC分类号： A61K31/7068 , A23L33/12 , A23L33/13 , A61B5/14532 , A61B5/4848 , A61B6/037 , A61B6/501 , A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61K51/0491 , A61K2300/00
摘要： The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof in the manufacture of a composition for use in a method for treating, stabilizing or slowing down brain glucose metabolism deficit in a subject in need thereof.
摘要翻译： 本发明涉及（i）尿苷和胞苷或其盐，磷酸盐，酰基衍生物或其酯中的一种或多种的用途，和（ii）包含二十二碳六烯酸（22:6; DHA）中的至少一种的脂质部分， ，二十碳五烯酸（20:5; EPA）和二十二碳五烯酸（22：5; DPA）或其酯在制备用于治疗，稳定或减缓受试者中的脑葡萄糖代谢缺陷的方法中的组合物 需要。
-
公开(公告)号：WO2014027885A1
公开(公告)日：2014-02-20
申请号：PCT/NL2013/050595
申请日：2013-08-13
申请人： N.V. NUTRICIA
IPC分类号： A61K31/14 , A61K31/202 , A61K31/7072 , A61P25/28
CPC分类号： A61K31/7072 , A61K31/14 , A61K31/202 , A61K31/4415 , A61K31/519 , A61K31/66 , A61K31/685 , A61K31/714 , A61K33/06 , A61K33/30 , A61K45/06 , A61K2300/00
摘要： This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8μM in a subject in need thereof, comprising administering to said subject a composition comprising 300 –900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.
摘要翻译： 本发明涉及在有需要的受试者中使用尿苷来源，优选尿苷单磷酸，用于增加，控制和/或维持4至8μM范围内的空腹血浆尿苷浓度，包括向所述受试者施用包含300 -900毫克所述尿苷源每日至少4周。 特别地，使用尿苷来源是预期的老年人和/或患有神经障碍如阿尔茨海默病和痴呆综合征的受试者。
-
公开(公告)号：WO2013066153A1
公开(公告)日：2013-05-10
申请号：PCT/NL2011/050739
申请日：2011-10-31
申请人： N.V. NUTRICIA , GROENENDIJK, Martine , BONGERS, Anke , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
IPC分类号： A61K31/202 , A61K31/7072 , A61K45/06 , A61P25/00
CPC分类号： A61K31/7072 , A23L33/12 , A23L33/13 , A23L33/40 , A61K31/14 , A61K31/202 , A61K45/06 , A61K2300/00
摘要： The invention relates to a composition comprising:(i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, for use in the improvement of the composite NTB score. The invention also provides an improved NTB method comprising an optimized set of individualized tests, in particular for a (prodromal or mild) Alzheimer's or dementia patient.
摘要翻译： 本发明涉及一种组合物，其包含：（i）尿苷和胞苷中的一种或多种，或其盐，磷酸酯，酰基衍生物或其酯; 和（ii）包含二十二碳六烯酸（22:6; DHA），二十碳五烯酸（20:5; EPA）和二十二碳五烯酸（22:5; DPA）或其酯中的至少一种的脂质部分，用于 提高复合NTB得分。 本发明还提供了一种改进的NTB方法，其包括优化的个体化测试集，特别是针对（前驱或轻度）阿尔茨海默氏症或痴呆患者的一组优化的测试。
-
公开(公告)号：WO2012091549A1
公开(公告)日：2012-07-05
申请号：PCT/NL2011/050556
申请日：2011-08-11
申请人： N.V. NUTRICIA , HAGEMAN, Robert, Johan, Joseph , DE WILDE, Mattheus, Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
发明人： HAGEMAN, Robert, Johan, Joseph , DE WILDE, Mattheus, Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick, Joseph, Gerardus, Hendrikus
IPC分类号： A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61P3/02 , A61P21/00 , A61P25/28
CPC分类号： A61K31/675 , A23L33/12 , A23L33/13 , A23L33/15 , A23L33/40 , A23V2002/00 , A61K31/14 , A61K31/20 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/661 , A61K31/683 , A61K31/685 , A61K31/70 , A61K31/7056 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , C07H19/052 , C07H19/06 , A61K2300/00 , A23V2200/316 , A23V2200/322 , A23V2250/1882 , A23V2250/304 , A23V2250/704 , A23V2250/156 , A23V2250/1626 , A23V2250/1844 , A23V2250/1846 , A23V2250/1848 , A23V2250/185 , A23V2250/1852 , A23V2250/1868 , A23V2250/187 , A23V2250/5424 , A23V2250/7052 , A23V2250/7058 , A23V2250/706 , A23V2250/308
摘要： Composition comprising at least two components, more preferably at least three com- ponents, more preferably at least four components, selected from the group of (i) a nu- cleoside equivalent, (ii) an ω-3 polyunsaturated fatty acid selected from the group of DHA, DPA and EPA, (iii) a vitamin B, (iv) a phospholipid, (v) an antioxidant and (vi) a choline, with the proviso that at least component (i) or (iii) is present, for use in the prevention or treatment of frailty in a mammal, wherein frailty is determined by com- pliance with at least 2 criterions, preferably 3 criterions, selected from the group of muscle weakness, excessive feelings of exhaustion or fatigue, abnormally low physical activity, slow or unsteady gait, weight loss, and neurological dysfunction.
摘要翻译： 组合物，其包含至少两种组分，更优选至少三种组分，更优选至少四种组分，所述组分选自（i）核苷当量，（ii）选自以下的α-3多不饱和脂肪酸 DHA，DPA和EPA组，（iii）维生素B，（iv）磷脂，（v）抗氧化剂和（vi）胆碱，条件是至少存在组分（i）或（iii） 用于预防或治疗哺乳动物的虚弱，其中通过符合从肌肉无力，疲劳或疲劳过度感觉，异常低体力活动组中选择的至少2个标准，优选3个标准来确定虚弱， 慢性或不稳定的步态，体重减轻和神经功能障碍。
-
7.发明申请
公开(公告)号：WO2009002166A1
公开(公告)日：2008-12-31
申请号：PCT/NL2008/050411
申请日：2008-06-20
申请人： N.V. Nutricia , KAMPHUIS, Patrick Joseph Gerardus Hendrikus , GROENENDIJK, Martine , BONGERS, Anke
IPC分类号： A61K31/20 , A23L1/29 , A23L1/30 , A23L1/304 , A23L1/305 , A61K31/14 , A61K31/202 , A61K31/7072 , A61P25/28 , A61P43/00
CPC分类号： A61K31/202 , A23L33/10 , A23L33/12 , A23L33/15 , A23L33/16 , A23L33/40 , A23V2002/00 , A61K31/14 , A61K31/557 , A61K31/7072 , A61K45/06 , A61K2300/00 , A23V2200/322 , A23V2250/1868
摘要： The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini -mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20 - 26, the memory impairment in the sub-group of 24 - 26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.
摘要翻译： 因此，本发明涉及组合物的用途，所述组合物包含：（a）尿苷或磷酸尿苷; 和（b）二十二碳六烯酸和/或二十碳五烯酸，用于改善记忆和/或治疗或预防受损记忆功能的受试者，小细胞状态检查为24-26，其中所述组合物肠内施用于 学科。 在MMSE测试中，任何得分为27或更高（30分之一）是有效的。 在痴呆症患者中，20-26岁轻度痴呆，10-19例中度痴呆，10例严重痴呆。 本发明人相信，在二十至二十六国集团内，二十四至二十六小组的记忆障碍甚至可逆，因为病理路径刚刚开始发展。 在这组受试者中，病理学途径刚刚开始发展。 这个亚组的临床研究显示出很好的结果。
-
8.发明申请METHOD FOR TREATING, STABILIZING OR SLOWING DOWN BRAIN GLUCOSE METABOLISM DEFICIT 审中-公开治疗，稳定或缓解脑部葡萄糖代谢缺陷的方法
公开(公告)号：WO2015115898A1
公开(公告)日：2015-08-06
申请号：PCT/NL2015/050064
申请日：2015-02-02
申请人： N.V. NUTRICIA
发明人： BROERSEN, Ladislaus Maria , HAGEMAN, Robert Johan Joseph , LANSBERGEN, Marieke , GROENENDIJK, Martine , DE WILDE, Mattheus Cornelis
IPC分类号： A23L1/30 , A61K45/06 , A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7068 , A61K31/7072 , A61K31/714 , A61K33/04 , A61P25/28
CPC分类号： A61K31/7068 , A23L33/12 , A23L33/13 , A61B5/14532 , A61B5/4848 , A61B6/037 , A61B6/501 , A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/519 , A61K31/683 , A61K31/685 , A61K31/7072 , A61K31/714 , A61K33/04 , A61K45/06 , A61K51/0491 , A61K2300/00
摘要： The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof in the manufacture of a composition for use in a method for treating, stabilizing or slowing down brain glucose metabolism deficit in a subject in need thereof.
摘要翻译： 本发明涉及（i）尿苷和胞苷或其盐，磷酸酯，酰基衍生物或酯中的一种或多种和（ii）包含以下物质中的至少一种的脂质部分的用途：二十二碳六烯酸 （22:6; DHA），二十碳五烯酸（20:5; EPA）和二十二碳五烯酸（22:5; DPA）或其酯在制备用于治疗，稳定或减缓 在有需要的受试者中脑葡萄糖代谢缺陷。
-
公开(公告)号：WO2013066168A1
公开(公告)日：2013-05-10
申请号：PCT/NL2012/050754
申请日：2012-10-30
申请人： N.V. NUTRICIA
IPC分类号： A61K31/202 , A61K31/7072 , A61K45/06 , A61P25/00
CPC分类号： A61K31/7072 , A23L33/115 , A23L33/12 , A23L33/13 , A23L33/15 , A61K31/14 , A61K31/202 , A61K31/355 , A61K31/375 , A61K31/519 , A61K31/675 , A61K31/7068 , A61K31/714 , A61K33/04 , A61K45/06 , G09B19/00 , A61K2300/00
摘要： The invention relates to a composition comprising: (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA),or esters thereof, for use in the improvement of the composite NTB score. The invention also provides an improved NTB method comprising an optimized set of individualized tests, in particular for a (prodromal or mild) Alzheimer's or dementia patient.
摘要翻译： 本发明涉及一种组合物，其包含：（i）尿苷和胞苷中的一种或多种，或其盐，磷酸酯，酰基衍生物或其酯; 和（ii）包含二十二碳六烯酸（22:6; DHA），二十碳五烯酸（20:5; EPA）和二十二碳五烯酸（22:5; DPA）或其酯中的至少一种的脂质部分，用于 提高复合NTB得分。 本发明还提供了一种改进的NTB方法，其包括优化的个体化测试集，特别是针对（前驱或轻度）阿尔茨海默氏症或痴呆患者的一组优化的测试。
-
公开(公告)号：WO2010095926A1
公开(公告)日：2010-08-26
申请号：PCT/NL2009/050078
申请日：2009-02-20
申请人： N.V. NUTRICIA , VAN DER BEEK, Eline Marleen , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
发明人： VAN DER BEEK, Eline Marleen , DE WILDE, Mattheus Cornelis , GROENENDIJK, Martine , KAMPHUIS, Patrick Joseph Gerardus Hendrikus
CPC分类号： A61K31/05 , A23L2/52 , A23L33/105 , A23L33/127 , A23V2002/00 , A23V2250/54246 , A23V2250/54252 , A23V2250/5114 , A23V2250/2132 , A23V2200/322
摘要： The present invention relates to the use of an hydroxylated stilbene, in particular resveratrol, in the manufacture of a neutraceutical composition for the treatment of age- and condition-related decline in brain neuronal function and/or cognitive functioning in a mammal. In particular, the condition is selected from the group of Alzheimer's Disease, dementia, depression, sleep disorders, impaired memory function, psychoses, Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, ADHD and anxiety.
摘要翻译： 本发明涉及羟基化二苯乙烯，特别是白藜芦醇在制备用于治疗哺乳动物的脑神经元功能和/或认知功能的年龄和状况有关的下降的营养组合物中的用途。 特别地，该病症选自阿尔茨海默氏病，痴呆，抑郁症，睡眠障碍，记忆障碍受损，精神病，帕金森病，亨廷顿舞蹈病，癫痫，精神分裂症，偏执狂，ADHD和焦虑症。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.017 秒)
